AlzeCure Pharma AB (SE:ALZCUR)
:ALZCUR
Want to see SE:ALZCUR full AI Analyst Report?
ALZCUR Stock Chart & Stats
kr2.44
kr0.16(7.05%)
At close: 4:00 PM EST
kr2.44
kr0.16(7.05%)
Day’s Range― - ―
52-Week Rangekr1.30 - kr4.95
Previous CloseN/A
Volume72.39K
Average Volume (3M)52.87K
Market Cap
kr168.92M
Enterprise Valuekr113.37M
Total Cash (Recent Filing)kr50.34M
Total Debt (Recent Filing)kr5.12M
Price to Earnings (P/E)―
Beta-0.14
Next Earnings
May 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding114,914,450
10 Day Avg. Volume28,042
30 Day Avg. Volume52,872
Financial Highlights & Ratios
PEG Ratio-1.94
Price to Book (P/B)6.11
Price to Sales (P/S)0.00
P/FCF Ratio-5.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.4
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageModest debt and a low debt-to-equity ratio provide durable financial flexibility for a pre-commercial biotech. Low leverage reduces near-term solvency pressure, making it easier to absorb R&D cycles, negotiate partnerships, or raise capital without immediate refinancing strain.
Out-licensing R&D Business ModelA partner-centric R&D model concentrates resources on discovery while limiting the need to build commercial infrastructure. Durably attractive for small biotech: successful deals can deliver upfront, milestone and royalty streams while shifting late-stage development cost and commercialization risk to larger pharma partners.
Signs Of Cash-flow Improvement TrendA year-to-year swing toward improved free cash flow, plus a prior positive operating year, suggests management can alter spend or program timing to reduce burn. If sustained, this structural improvement lessens funding pressure and increases runway predictability over the next several months.
Bears Say
No Revenue And Persistent LossesBeing pre-commercial with consecutive sizable net losses means the core business does not yet generate operating cash. Over 2–6 months this structural state forces reliance on external funding or deal execution to advance programs, constraining strategic optionality if losses continue.
Negative Operating And Free Cash FlowConsistent negative operating and free cash flow indicates structural cash burn from R&D activities. Overcoming this requires recurrent financing or licensing deals; otherwise, continued cash depletion can force dilutive equity raises or program cuts that materially affect long-term value creation.
Eroding Equity And Heightened Funding RiskMarked decline in equity over several years signals cumulative losses and reduces the cushion against future setbacks. This structural erosion raises the probability management must seek external capital sooner, increasing dilution risk and constraining long-term project financing options.
ALZCUR FAQ
What was AlzeCure Pharma AB’s price range in the past 12 months?
AlzeCure Pharma AB lowest stock price was kr1.30 and its highest was kr4.95 in the past 12 months.
What is AlzeCure Pharma AB’s market cap?
AlzeCure Pharma AB’s market cap is kr168.92M.
When is AlzeCure Pharma AB’s upcoming earnings report date?
AlzeCure Pharma AB’s upcoming earnings report date is May 05, 2026 which is in 2 days.
How were AlzeCure Pharma AB’s earnings last quarter?
AlzeCure Pharma AB released its earnings results on Feb 26, 2026. The company reported -kr0.154 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.154.
Is AlzeCure Pharma AB overvalued?
According to Wall Street analysts AlzeCure Pharma AB’s price is currently Overvalued.
Does AlzeCure Pharma AB pay dividends?
AlzeCure Pharma AB does not currently pay dividends.
What is AlzeCure Pharma AB’s EPS estimate?
AlzeCure Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AlzeCure Pharma AB have?
AlzeCure Pharma AB has 114,914,450 shares outstanding.
What happened to AlzeCure Pharma AB’s price movement after its last earnings report?
AlzeCure Pharma AB reported an EPS of -kr0.154 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.188%.
Which hedge fund is a major shareholder of AlzeCure Pharma AB?
Currently, no hedge funds are holding shares in SE:ALZCUR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AlzeCure Pharma AB
AlzeCure Pharma AB (ALZCUR) is a Swedish pharmaceutical company that focuses on developing innovative therapies for neurodegenerative diseases, with a particular emphasis on Alzheimer's disease and pain management. The company operates in the biotechnology sector, leveraging its expertise in neuroscience to advance its pipeline of drug candidates. AlzeCure's core products include a range of proprietary small molecule drugs that target key pathways involved in neurodegeneration.
Technical Analysis
Orexo AB
―
Klaria Pharma Holding AB
―
Nanexa AB
―
Enzymatica AB
―
Enorama Pharma AB
―